CS MEDICA A/S (“CS MEDICA” or “the Company”) announces today that the Company have entered in dialog with a European based veterinarian company, with a long track record, branding their products to veterinary practices throughout Europe. The Company is hereby looking into entering the veterinarian market with the Company’s Veterinary Medical CBD Products before schedule.

CS MEDICA have brought effective medical CBD products to humans, and now they want to utilize their knowledge of effective Medical CBD Products by bringing the veterinarian (vet) Medical CBD Products to the family’s best friends: dog, cat and horses.

New market & potential partner
CS MEDICA have entered dialog with a European based veterinarian company, with a long track record, branding their products to veterinary practices throughout Europe. There is a general need in the vet marked for new products especially those products, available from CS MEDICA.  This was one of the main reasons for the company’s interest in the CANNASEN CBD vet product line.  See more about the need of new treatments in the attached appendix, wich among others disclose the many side effects and antibiotics resistance in the current products available at the vet marked.

Upon final confirmation of this collaboration, CS MEDICA will accelerate the final test covering the CANNASEN CBD vet product line and launch the product line in cooperation with this company.  These tests have now been initiated and thereby the company now pull forward the previous announced date for initiation (second half of 2022/2023).

The vet area is a big potential market for CS MEDICA.  In 2020, 8% of the total US CBD market was concentrated in the VET area.  With a US CBD marked in 2021 of US$[1] 7,7 Billion – 8% of this marked equals: US$ 0,62 Billion.  Looking towards Europe, the CBD market in 2021 amounted to US$ 5,1 Billion, with an expected growth to US$ 15.4 Billion in 2028. Correspondingly[2]; 8% of this market in 2028 equals to: US$ 1,23 Billion being the Veterinarian CBD market in Europe.

Animal Wound Care Market: The global market is valued 1,2 Billion US$ in 2022 growing with a CAGR 7,3% to US$ 1,7 Billion in 2027.[3]

Animal antibiotics market: The global market is valued at US$ 1.43billion in 2022 and is expected to exhibit a CAGR of 3.8% during the forecast period (2022-2030) and to surpass US$ 1,93 Billion in 2030.[4] The main sales is antibiotic infused feed to livestock.

CS MEDICA potential – Veterinary Markets & Market share
CS MEDICA sees a great value within the vet area – and the specific marked within wound and pain, covered by the products introduced by CS MEDICA, the see the following market potentials.

Assuming that the market size of the global animal topical market is the same percentage of the total animal wound market, as the human topical wound market vs the general human wound care market, we have a ration of 6,78% in 2022 figures (1,43/20,8 billion US$[5]^,[6])

The total potential animal topical wound market based on above equals to: US$ 82,5 mio. in DKK: 603,22 mio. ( US 1,2 Billion[7] 1 *6,875%)

The global animal pain market is valued US$ 1,35 Billion in 2021 and expected to increase with a CAGR% of 6,6%, to US$ 2,0 billion in 2027.[8] From the Table below, it shows that the Osteoarthritis/NSAIDS counts for approx. 70% of the total market: 0,7*1,35= *US$ 0,95 Billion*, equals 6,95 billion DKK in 2021 and expected to increase to 0,7*2,0= 1,4 US$( DKK 10,24 billion) in 2027.

Based on these market sizes the company expects to enter a specific market size of 1B$, with them expeting the following potential market share and a related revenue of a total of DKK 99,5 million/yearly.

The Veterinary market is assessable for the company with an additional R&D investment of DKK 0,75 million – with a potential market value yearly of DKK 99,5 million/yearly

Disclaimer
Some statements may contain forward-looking information. All statements, other than of historical fact, that address activities, events, or developments that the Company believes, expects, or anticipates will or may occur in the future (including, without limitation, statements regarding potential distributor agreements) are forward-looking statements. Forward-looking statements are subject to several risks and uncertainties, many of which are beyond the Company’s ability to control or predict, which may cause the actual results of the Company to differ materially from those discussed in the forwardlooking statements.

Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described, there may be other factors that cause results or events not to be as anticipated, estimated or intended. The forward-looking statements included in this report are made as of the date of this press release and the Company does not undertake any obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

For more information about CS MEDICA, please contact:
Lone Henriksen, CEO
Phone: + (45) 71 20 30 47
Email: lh@galaxapharma.com
Website: https://www.cs-medica.com/

CS MEDICA A/S is a Danish medico cannabis company founded in 2011. CS MEDICA is committed to developing, manufacturing, and commercializing over-the-counter (OTC) medical device products containing cannabinoids. The Company runs its business through the two fully-owned subsidiaries, Galaxa Pharma A/S (distributor and representative of foreign manufacturers in the Nordic, registered medical device product distributor) and CanNordic A/S (Medical device developer and seller (BtB), registered medical device product manufacturer). CS MEDICA distributes products across the European borders and is headquartered in Copenhagen, Denmark.

The company is listed on Spotlight Stock Market in Stockholm (symbol: “CSMED”). For more information about CS MEDICA cs-medica.com.